The phase III Zostavax Efficacy and Safety Trial of 1 dose of licensed zoster vaccine ( ZV ; Zostavax ; Merck ) in 50-59-year-olds showed approximately 70 % vaccine efficacy ( VE ) to reduce the incidence of herpes zoster ( HZ ) .